Inclusion Criteria:
- consent form signed
- Age >= 18
- Carcinomatosis pre operative known or discivered in intraoperative
- Patients uin good general condition who may have extent surgery associated to specific inflammatory syndrom of immunotherapy
- Patients in good general condition
- Patient insured to social care
Inclusion Criteria (intraoperative):
- Gastric adenocarcinoma with macroscopic peritoneal carcinomatosis (PC) confirmed by extemporaneous histological examination
- CP extension minimal or moderate (peritoneal index ≤ 12).
- Resection of the entire macroscopic lesions detectable (primary tumor, lymph nodes and CP). cleaning D2 lymph node (or D1.5).
Exclusion Criteria:
- Presence of metastasis in reach
- Previous treatment with a non-humanized monoclonal AC- (mice or rat)
- Hypersensitivity to any type of antibody.
- History of cancer within 5 years preceding the entry in the trial other than basal cell skin carcinoma or in situ of the cervix,
- Patients already included in another clinical trial with experimental molecule
- Pregnant, or likely to be or breastfeeding, (Women of childbearing potential should have a pregnancy test (blood) negative 15 days before the date of the surgery) Using of a suitable method of contraception for patients of childbearing age during treatment. adequate contraception Methods includeare: an intrauterine device, hormonal contraception, condom use combined with a spermicide
- Persons deprived of liberty or Trust (including curatorship)
- Unable to undergo medical test for geographical, social or psychological.
Exclusion Criteria (intraoperative):
- Persistent peritoneal lesions visible to the end of the surgery
- Resection of the tail of the pancreas or pancreatic break (because no drainage post-op); break pleural (for K cardia)
- Presence of metastasis in reach during surgery (except for ovarian metastasis